Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 10 | 0.91 |
| pathways Reactome | 3 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 12337
Sealed predictions
- ATP5MC1 in dopamine neurons, braak+0.66 (p 0.053) → +0.63 (p 0.067)receipt 12344
Swarm cases
receipt 12344: ATP5MC1 in dopamine neurons, braak
- power
- full sample +0.54 (p 0.019, n 18), 95% CI +0.10 to +0.81. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.58 (p 0.013, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.62 (p 0.0060, n 18). not the mix.
- skeptic
- leave-one-out range +0.49 to +0.70, sign flips 0; without severely affected donors +0.54 (p 0.019, n 18). robust.
- cell type
- strongest in microglia: +0.73 (p 5.6e-4, n 18) vs +0.54 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATP5MC1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ATP5MC1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.30 p 0.286 (needs p < 1.8e-4)
Receipts
loading the receipts